Clinical trials: Psoriasis Patients
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Psoriasis, Psoriasis; Plaque
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with…
- Conditions
- Psoriasis, Psoriasis; Plaque, Psoriasis Vulgaris
- Trial name
- CERAMOL PSOR C (NCT07849101)
- Testing
- Narrowband UVB Phototherapy, Ceramol PSOR Cream, Comparator Emollient Cream
- Where
- 3 sites in Spain
- Volunteers
- 128 people
- Sponsor
- Unifarco SpA
Psoriatic Arthritis, Psoriasis
Psoriatic Arthritis and Psoriasis Treatment Decision Aid
The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.
- Trial name
- DA (NCT03737045)
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Pennsylvania
Psoriasis
Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.
- Trial name
- NCT00823693
- Testing
- Bimosiamose Cream
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- Revotar Biopharmaceuticals AG
Psoriasis, Parapsoriasis
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab.
- Trial name
- NCT00106847
- Testing
- Infliximab
- Volunteers
- 683 people
- Sponsor
- Centocor, Inc.
Psoriasis Vulgaris
Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris
The combination of calcipotriol and betamethasone dipropionate used in an ointment formulation (Daivobet® ointment) has shown to have an excellent efficacy and safety in the short-term and long-term management of psoriasis…
- Trial name
- TRIANGLE (NCT02004574)
- Testing
- Calcipotriol/betamethasone dipropionate gel
- Where
- South Korea
- Volunteers
- 201 people
- Sponsor
- Jooheung Lee
Psoriasis
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
- Trial name
- NCT02933528
- Testing
- DSXS Topical product
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- OASIS-1 (NCT03482011)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Germany and 7 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis
The purpose of this study is to investigate, whether FP187 is effective in the treatment of mild to moderate psoriatic arthritis.
- Trial name
- NCT02475304
- Testing
- FP187
- Where
- Sweden
- Sponsor
- Skane University Hospital
Plaque Psoriasis
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2306 with Cosentyx in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05377944
- Testing
- BAT2306, EU-approved Cosentyx
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Bio-Thera Solutions
Psoriasis Vulgaris
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
- Trial name
- NCT00287547
- Testing
- CTLA4Ig / Abatacept
- Where
- 10 sites in United States
- Volunteers
- 144 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ankylosing Spondylitis, Rheumatoid Arthritis (RA)
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease
The aim of this study is to compare the construct validity (convergent validity and known-groups validity) and responsiveness of EQ-5D-3L and EQ-5D-5L in patients with inflammatory joint disease.
- Conditions
- Ankylosing Spondylitis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Polyarthritis
- Trial name
- NCT07580092
- Testing
- EQ-5D-5L
- Where
- Sweden
- Volunteers
- 6,967 people
- Sponsor
- Karolinska Institutet
Arthritis, Psoriatic
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes…
- Trial name
- PEGASUS (NCT07532226)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag Ltd.
Spondylitis, Ankylosing, Psoriatic Arthritis
Enhanced Clinics for Patients Diagnosed With Ankylosing Spondylitis and Psoriatic Arthritis
The 19.5 months project will pilot the introduction of a hospital-based, nurse-led ankylosing spondylitis (AS) and psoriatic arthritis (PsA) service for patients being initiated on biologic therapy in NHS Lothian Edinburgh…
- Trial name
- ECAP (NCT04341233)
- Sponsor
- NHS Lothian
Psoriasis Vulgaris
Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients
Biologic such as guselkumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a 'one dose fits all'…
- Trial name
- BIOLOPTIM-GUS (NCT04080648)
- Testing
- Venapuncture, Patient questionnaires
- Where
- 7 sites in Belgium
- Volunteers
- 79 people
- Sponsor
- University Hospital, Ghent
Dermatologic Disease, Phobia
Efficacy of Targeted Intervention for Topical Steroid Phobia.
Topical steroids are an important component of treatment for many dermatological conditions, however 'Corticosteroid phobia' is a significant factor contributing to non adherence to prescribed therapy.
- Conditions
- Dermatologic Disease, Phobia, Adherence, Medication
- Trial name
- NCT03658252
- Testing
- Targeted education, Online disease specific forum
- Where
- Singapore
- Volunteers
- 270 people
- Sponsor
- National University Health System, Singapore
Rheumatoid Arthritis, Ankylosing Spondylitis
bIosimilar of aDalimumab, an European evAluation
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn Disease
- Trial name
- IDEA (NCT05190484)
- Volunteers
- 1,050 people
- Sponsor
- Fresenius Kabi
Plaque Psoriasis
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque…
- Trial name
- EVERLAST-A (NCT07090330)
- Testing
- ORKA-001 Induction Dose, ORKA-001 Maintenance Dose
- Where
- 26 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Oruka Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.